ProfileGDS5678 / 1456711_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 34% 33% 33% 32% 32% 32% 31% 32% 32% 32% 32% 33% 32% 33% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7995434
GSM967853U87-EV human glioblastoma xenograft - Control 22.7427633
GSM967854U87-EV human glioblastoma xenograft - Control 32.7466633
GSM967855U87-EV human glioblastoma xenograft - Control 42.6848532
GSM967856U87-EV human glioblastoma xenograft - Control 52.6847532
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8012132
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7504831
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7214132
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7126932
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7205132
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7292532
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7156133
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7393632
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7341933